Gut microbiota modulation as a promising therapy with metformin in rats with non-alcoholic steatohepatitis: Role of LPS/TLR4 and autophagy pathways

• Published in: European journal of pharmacology 2020-11, Vol.887, p.173461, Article 173461
• Main Authors: Ahmed, Lamiaa A., Salem, Maha B., Seif el-Din, Sayed H., El-Lakkany, Naglaa M., Ahmed, Hend O., Nasr, Sami M., Hammam, Olfat A., Botros, Sanaa S., Saleh, Samira
• Format: Article
• Language: English
• Subjects: Animals; Autophagy; Autophagy - drug effects; Autophagy - physiology; Diet, High-Fat - adverse effects; Drug Therapy, Combination; Gastrointestinal Microbiome - drug effects; Gastrointestinal Microbiome - physiology; Hypoglycemic Agents - administration & dosage; Lactobacillus reuteri; Lipopolysaccharides - toxicity; Male; Metformin - administration & dosage; Metronidazole; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic steatohepatitis; Probiotics - administration & dosage; Random Allocation; Rats; Rats, Sprague-Dawley; Short chain fatty acids; Toll-Like Receptor 4 - metabolism
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2020.173461

Gut microbiota is a crucial factor in pathogenesis of non-alcoholic steatohepatitis (NASH). Therefore, targeting the gut–liver axis might be a novel therapeutic approach to treat NASH. This study aimed to investigate the therapeutic effects of a probiotic (Lactobacillus reuteri) and metronidazole (MTZ) (an antibiotic against Bacteroidetes) either alone or in combination with metformin (MTF) in experimentally-induced NASH. NASH was induced by feeding rats high fat diet (HFD) for 12 weeks. MTF (150 mg/kg/day) or L. reuteri (2x109 colony forming unit/day) were given orally for 8 weeks; meanwhile, MTZ (15 mg/kg/day, p.o.) was administered for 1 week. Treatment with L. reuteri and MTZ in combination with MTF showed additional benefit compared to MTF alone concerning lipid profile, liver function, oxidative stress, inflammatory and autophagic markers. Furthermore, combined regimen succeeded to modulate acetate: propionate: butyrate ratios as well as Firmicutes and Bacteroidetes fecal contents with improvement of insulin resistance (IR). Yet, the administration of MTF alone failed to normalize Bacteriodetes and acetate contents which could be the reason for its moderate effect. In conclusion, gut microbiota modulation may be an attractive therapeutic avenue against NASH. More attention should be paid to deciphering the crosstalk mechanisms linking gut microbiota to non-alcoholic fatty liver disease (NAFLD) to identify new therapeutic targets for this disease. [Display omitted]